Skip to main content

Talk Bio

Search This Blog

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

on April 28, 2025

Get link
Facebook
X
Pinterest
Email
Other Apps

Merck KGaA Acquires SpringWorks Therapeutics for $3.9 Billion

Sources:

Aggressive disease treatments Fibromatosis Gomekli KGaA Merck KGaA Neurofibromatosis 1 Ogsiveo Pfizer pharmaceutical acquisition SpringWorks

Get link
Facebook
X
Pinterest
Email
Other Apps

Contact Form

Name

Email *

Message *

Popular Posts

Thermo Fisher Scientific Continues Workforce Reduction with 300 Layoffs in Massachusetts

Thermo Fisher Scientific is laying off 300 employees at its viral vector facilities in Cambridge and Plainville, Massachusetts 6 . The layoffs are expected to begin on March 30, 2025, according to a WARN notice 9 . This is part of an ongoing series of workforce reductions by Thermo Fisher, following previous cuts in 2023 and 2024 2 . The company is restructuring its viral vector production network, which is used in the manufacturing of cell and gene therapies 2 . These cuts reflect changes in demand for viral vectors and Thermo Fisher's efforts to optimize resources across its manufacturing network 2 . The layoffs are part of a broader trend of job cuts in the biotechnology and pharmaceutical industries, with many companies implementing cost-saving measures 1 4 . Thermo Fisher's global headcount decreased from approximately 130,000 at the end of 2022 to approximately 122,000 at the end of 2023 2 . The company has been particularly active in reducing its workforce ...

Sanofi's Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

Beyfortus reached blockbuster status in its first full year, with sales of €1.7 billion ($1.77 billion) in 2024 10 . In Q3 2024, Beyfortus brought in nearly $700 million, representing a 381% year-over-year increase 1 . Sanofi expects Q4 Beyfortus sales to be similar to Q3, implying full-year 2024 sales of approximately €1.5 billion 1 . The strong performance of Beyfortus contributed to a 25% year-over-year growth in Sanofi's vaccines division 1 . Beyfortus is now protecting babies in more than 20 countries 7 . The US market is anticipated to have enough supply for every eligible baby to have access to immunization 4 . Sanofi is collaborating with AstraZeneca on Beyfortus development and manufacturing, with new filling lines approved to expand supply 4 . Beyfortus is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease in newborns and infants 4 . The global Beyfortus market is expected to see significan...

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

Eli Lilly has entered into two strategic collaborations to advance its oncology and metabolic disease portfolios 1 2 4 . Lilly partnered with AdvanCell, an Australian radiopharmaceutical company, to develop targeted alpha therapies for cancer treatment 1 3 5 . The collaboration with AdvanCell will leverage their proprietary Pb-212 production technology and radionuclide development infrastructure 1 2 . Lilly also signed an agreement with OliX Pharmaceuticals, a South Korean biotech firm, to develop treatments for metabolic dysfunction-associated steatohepatitis (MASH) and other cardiometabolic diseases 4 6 . The OliX deal centers on OLX75016, a small interfering RNA therapy targeting the MARC1 enzyme, currently in Phase I trials for MASH 4 6 . Financial details of both collaborations were not fully disclosed, though OliX will receive an initial payment from Lilly to complete the Phase I trial of OLX75016 6 8 . These partnerships align with Lilly's strategy to expand its ...

Powered by Blogger